These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 38458640)

  • 1. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy.
    Wang S; Li Y; Xu C; Dong J; Wei J
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8
    Wei W; Tian L; Zheng X; Zhong L; Chen Y; Dong H; Zhang G; Wang S; Tong X
    Oncoimmunology; 2024; 13(1):2322173. PubMed ID: 38419758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
    Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic vaccinia virus acts synergistically with anti-PD-L1 antibody to enhance the killing of colon cancer cells by CD8
    Wu R; Tong S; Yin J; Zhu Z; Mao Z; Xu L
    Pathol Res Pract; 2023 Jul; 247():154535. PubMed ID: 37257241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment.
    Azar F; Deforges J; Demeusoit C; Kleinpeter P; Remy C; Silvestre N; Foloppe J; Fend L; Spring-Giusti C; Quéméneur E; Marchand JB
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
    Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing therapeutic efficacy of oncolytic vaccinia virus armed with Beclin-1, an autophagic Gene in leukemia and myeloma.
    Lei W; Wang S; Xu N; Chen Y; Wu G; Zhang A; Chen X; Tong Y; Qian W
    Biomed Pharmacother; 2020 May; 125():110030. PubMed ID: 32187960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.
    Li M; Zhang M; Ye Q; Liu Y; Qian W
    Cancer Biol Med; 2023 Aug; 20(9):646-61. PubMed ID: 37615308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
    Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
    Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
    Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering oncolytic vaccinia virus with functional peptides through mild and universal strategy.
    Huang LL; Li X; Liu K; Zou B; Xie HY
    Anal Bioanal Chem; 2019 Feb; 411(4):925-933. PubMed ID: 30523361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Embelin Promotes Oncolytic Vaccinia Virus-Mediated Antitumor Immunity Through Disruption of IL-6/STAT3 Signaling in Lymphoma.
    Wang P; Wu Y; Yang C; Zhao G; Liu Y; Cheng G; Wang S
    Onco Targets Ther; 2020; 13():1421-1429. PubMed ID: 32110041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.
    Lou J; Dong J; Xu R; Zeng H; Fang L; Wu Y; Liu Y; Wang S
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34060602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.
    Ekeke CN; Russell KL; Murthy P; Guo ZS; Soloff AC; Weber D; Pan W; Lotze MT; Dhupar R
    J Thorac Cardiovasc Surg; 2022 Apr; 163(4):e313-e328. PubMed ID: 33485667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.